Therefore, the focus of the research field in DKD should be on conducting large clinical trials that evaluate the action of the most promising molecules that target the NRF2/KEAP1/ARE pathway, paving the way for an important breakthrough that can alleviate this heavy burden. Here, NFE2L2 is linked to diabetic kidney disease.